Professor Iain McInnes Reviews the Most Important Papers from 2017

Please click the links below to go to the CSF review of each paper.

2017 was a successful year for rheumatoid arthritis research, with some key advances in JAK inhibitors and IL-6 inhibitors, as outlined below. -Tofacitinib was suggested as a potential treatment for psoriatic arthritis, and NICE recommended tofacitinib as a treatment for moderate to severe rheumatoid arthritis-Baricitinib studies supported the potential use of baricitinib as a treatment for rheumatoid arthritis -Filgotinib Phase 2 studies suggested that filgotinib could be effective as monotherapy or combination therapy for the treatment of rheumatoid arthritis-Upadacitinib was efficacious in Phase 2 studies and entered Phase 3-Subcutaneous tocilizumab proved efficacious and had a comparable safety profile to intravenous tocilizumabTofacitinib: Efficacy and Safety of Tofacitinib Monotherapy, Tofacitinib with Methotrexate, and Adalimumab with Methotrexate in Patients with Rheumatoid Arthritis (ORAL Strategy): A Phase 3b/4, Double-Blind, Head-To-Head, Randomised Controlled Trial.The Lancet - Fleischmann R, Mysler E, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.The New England Journal of Medicine - Gladman D, Rigby W, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. The New England Journal of Medicine - Mease P, Hall S, et al.Baricitinib: Baricitinib in Patients with Inadequate Response or Intolerance to Conventional Synthetic DMARDs: Results from the RA-BUILD Study.Annals of Rheumatic Diseases - Dougados M, van der Heijde D, et al. Safety and Efficacy of Baricitinib through 128 Weeks in an Open-label, Long-term Extension Study in Patients with Rheumatoid Arthritis.The Journal of Rheumatology - Keystone EC, Genovese MC, et al.Filgotinib: Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Annuls of Rheumatic Diseases - Westhovens R, Taylor PC, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).Annuls of Rheumatic Diseases - Kavanaugh A, Kremer J, et al.Upadacitinib: A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy.Arthritis & Rheumatology - Kremer JM, Emery P, et al.Tocilizumab: Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-naïve Patients with Early Rheumatoid Arthritis: 2-year Clinical and Radiographic Results from the Randomized, Placebo-controlled FUNCTION Trial. Annuls of Rheumatic Diseases - Burmester GR, Rigby WF, et al.Review: Pathogenetic Insights from the Treatment of Rheumatoid Arthritis.The Lancet - McInnes I, Schett G.

LinkedIn